154 related articles for article (PubMed ID: 35818588)
1. Rational identification of small molecules derived from 9,10-dihydrophenanthrene as potential inhibitors of 3CL
Daoui O; Elkhattabi S; Chtita S
Struct Chem; 2022; 33(5):1667-1690. PubMed ID: 35818588
[TBL] [Abstract][Full Text] [Related]
2. A computer-aided drug design approach to explore novel type II inhibitors of c-Met receptor tyrosine kinase for cancer therapy: QSAR, molecular docking, ADMET and molecular dynamics simulations.
Daoui O; Nour H; Abchir O; Elkhattabi S; Bakhouch M; Chtita S
J Biomol Struct Dyn; 2023; 41(16):7768-7785. PubMed ID: 36120976
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
4. The anti-SARS-CoV-2 activity of novel 9, 10-dihydrophenanthrene derivatives: an insight into molecular docking, ADMET analysis, and molecular dynamics simulation.
Yamari I; Abchir O; Mali SN; Errougui A; Talbi M; Kouali ME; Chtita S
Sci Afr; 2023 Sep; 21():e01754. PubMed ID: 37332393
[TBL] [Abstract][Full Text] [Related]
5. Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties.
Khaldan A; Bouamrane S; En-Nahli F; El-Mernissi R; El Khatabi K; Hmamouchi R; Maghat H; Ajana MA; Sbai A; Bouachrine M; Lakhlifi T
Heliyon; 2021 Mar; 7(3):e06603. PubMed ID: 33817388
[TBL] [Abstract][Full Text] [Related]
6. Exploration of chalcones as 3-chymotrypsin-like protease (3CL
Lam TP; Nguyen DN; Mai TT; Tran TD; Le MT; Huynh PNH; Nguyen DT; Tran VH; Trinh DT; Truong P; Vo CT; Thai KM
Struct Chem; 2022; 33(5):1707-1725. PubMed ID: 35811783
[TBL] [Abstract][Full Text] [Related]
7. QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CL
Soleymani N; Ahmadi S; Shiri F; Almasirad A
BMC Chem; 2023 Apr; 17(1):32. PubMed ID: 37024955
[TBL] [Abstract][Full Text] [Related]
8. Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL
Mathpal S; Joshi T; Sharma P; Pande V; Chandra S
Struct Chem; 2022; 33(5):1815-1831. PubMed ID: 35153452
[TBL] [Abstract][Full Text] [Related]
9. QSAR, homology modeling, and docking simulation on SARS-CoV-2 and pseudomonas aeruginosa inhibitors, ADMET, and molecular dynamic simulations to find a possible oral lead candidate.
Edache EI; Uzairu A; Mamza PA; Shallangwa GA
J Genet Eng Biotechnol; 2022 Dec; 20():88. PubMed ID: 35730025
[TBL] [Abstract][Full Text] [Related]
10. Antiviral phytocompounds "ellagic acid" and "(+)-sesamin" of
Umar AK; Zothantluanga JH; Aswin K; Maulana S; Sulaiman Zubair M; Lalhlenmawia H; Rudrapal M; Chetia D
Struct Chem; 2022; 33(5):1445-1465. PubMed ID: 35571865
[TBL] [Abstract][Full Text] [Related]
11. In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.
Ghaleb A; Aouidate A; Ayouchia HBE; Aarjane M; Anane H; Stiriba SE
J Biomol Struct Dyn; 2022 Jan; 40(1):143-153. PubMed ID: 32799761
[TBL] [Abstract][Full Text] [Related]
12. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
13. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
[TBL] [Abstract][Full Text] [Related]
14. Study on the mechanism of active components of Liupao tea on 3CL
Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
[TBL] [Abstract][Full Text] [Related]
15. The SARS-CoV-2 main protease (M
Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB
MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352
[TBL] [Abstract][Full Text] [Related]
16. In silico approach for the development of novel antiviral compounds based on SARS-COV-2 protease inhibition.
Ničkčović VP; Nikolić GR; Nedeljković BM; Mitić N; Danić SF; Mitić J; Marčetić Z; Sokolović D; Veselinović AM
Chem Zvesti; 2022; 76(7):4393-4404. PubMed ID: 35400796
[TBL] [Abstract][Full Text] [Related]
17. Design of new small molecules derived from indolin-2-one as potent TRKs inhibitors using a computer-aided drug design approach.
Haloui R; Mkhayar K; Daoui O; El Khattabi K; El Abbouchi A; Chtita S; Elkhattabi S
J Biomol Struct Dyn; 2024 Jan; ():1-18. PubMed ID: 38217880
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential binders of the main protease 3CL
Macchiagodena M; Pagliai M; Procacci P
Chem Phys Lett; 2020 Jul; 750():137489. PubMed ID: 32313296
[TBL] [Abstract][Full Text] [Related]
19. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
Keretsu S; Bhujbal SP; Cho SJ
Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
[TBL] [Abstract][Full Text] [Related]
20.
Khan PM; Kumar V; Roy K
Comb Chem High Throughput Screen; 2021; 24(8):1281-1299. PubMed ID: 32928086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
